Study of the mdrl Gene in Multidrug Resistant Lung Cancer Cells
Author Information
Author(s): J.G. Reeve, P.H. Rabbitts, P.R. Twentyman
Primary Institution: MRC Clinical Oncology and Radiotherapeutics Unit, Medical Research Council Centre
Hypothesis
Is P-glycoprotein hyperexpression a clinically relevant component of multidrug resistance in small cell lung cancer?
Conclusion
The study found that the H69/LX4 cell line shows amplification and expression of the P-glycoprotein gene, suggesting its role in multidrug resistance.
Supporting Evidence
- H69/LX4 shows amplification and expression of the P-glycoprotein gene.
- H69/AR does not show amplification or over-expression of the mdrl gene.
- Resistance to multiple drugs is often associated with over-production of P-glycoproteins.
Takeaway
Some lung cancer cells can become resistant to many drugs, and this study found that one type of resistant cell has a lot of a protein that helps it push out the drugs.
Methodology
The study involved deriving a multidrug resistant variant of the NCI-H69 cell line and analyzing the amplification and expression of the mdrl gene.
Limitations
The study does not provide evidence of mdrl gene expression in SCLC cell lines from drug-treated patients.
Want to read the original?
Access the complete publication on the publisher's website